[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adolescent-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adolescent-obesity":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,43,69,98,132,165,194,219,249,273,302,331],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100642158","comparison-of-day-hospitalization-versus-full-time-hospitalization-in-the-treatment-of-severe-adolescent-obesity-100642158",false,"NCT07652190","Comparison of Day Hospitalization Versus Full-Time Hospitalization in the Treatment of Severe Adolescent Obesity","Comparison of Day Hospitalization and Full-Time Hospitalization in the Treatment of Severe Adolescent Obesity (MAROSA)","MAROSA","Inclusion Criteria:\n\n* Adolescents aged 12-20 years\n* Severe obesity (IOTF \\> 30)\n* Admitted to participating centers\n* Covered by health insurance\n* Signed informed consent (participant or legal guardian)\n\nExclusion Criteria:\n\n* Acute psychiatric disorder requiring hospitalization\n* Secondary obesity due to endocrine disorders\n* Age \\\u003C 12 or \\> 20 years\n* Inability to provide consent Emergency situation Refusal to participate","ALL","12 Years","20 Years",{"count":21,"type":22},126,"ESTIMATED","INTERVENTIONAL",[25],"NA","This multicenter prospective quasi-experimental study aims to compare the effectiveness of day hospitalization versus full-time hospitalization for adolescents with severe obesity. The primary outcome is the change in BMI z-score measured six months after the end of treatment.",[28,29,30],"Severe Adolescent Obesity","Adolescent Obesity","Pediatric Obesity","NOT_YET_RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":22},"2026-10-05",{"date":39,"type":22},"2027-11-10",{"name":41,"class":42},"Fondation Santé des Étudiants de France","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100426790","self-weighing-for-adolescents-seeking-obesity-treatment-100426790","NCT04837586","Self-Weighing for Adolescents Seeking Obesity Treatment","Self-weighing for Weight Management in Adolescents Seeking Obesity Treatment: A Randomized Pilot","Inclusion Criteria for Adolescent:\n\n* Ages 12 to \\\u003C 18 years\n* Body mass index (BMI) \\>\u002F= 95th percentile\n\nExclusion Criteria for Adolescent:\n\n* Score over 20 on the Eating Attitudes Test (EAT-26)\n* Any unhealthy weight control behaviors\n* Severe anxiety or depression\n* Participation in another Pediatric Weight Management Clinic study\n* Developmental delay\n* Significant co-morbidity that might cause weight fluctuations in weight\n* Current participation in a weight loss research study\n\nInclusion Criteria for Parent:\n\n* Parent or legal guardian of the child participant\n* Parent aged \\> 18 years","17 Years",{"count":52,"type":22},99,[25],"99 patients age 12 to \\\u003C18 years old with obesity (BMI \\>\u002F=95th percentile), will be randomized to one of three treatment interventions:\n\n1. Usual Care\n2. Usual Care plus advice to weigh daily on simple scale\n3. Usual Care plus advice to weigh-daily on an EHR-connected scale\n\nSurvey data collected at baseline, 2, 4, 6, and 12-weeks, and qualitative interviews at 12 weeks, will assess acceptability, safety, self-efficacy, and BMI. Recruitment will also be assessed (% eligible patients who consent). In order to understand real-world feasibility of this intervention, the clinic staff will work with patients to connect the scales to Epic.",[29],[57],"Obesity","RECRUITING","2026-05-18",{"date":61,"type":35},"2026-05-20",{"date":63,"type":35},"2023-09-15",{"date":65,"type":22},"2026-10-01",{"name":67,"class":42},"University of Minnesota",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":68},"100583634","type-1-diabetes-adolescents-for-healthier-lifestyles-study-100583634","NCT06878872","Type 1 Diabetes Adolescents for Healthier Lifestyles Study","Adapting an Adolescent Weight Management Program for a Type 1 Diabetes Population","T1DAL","Inclusion Criteria:\n\n* Teen diagnosed with type 1 diabetes at least 6 months ago\n* Teen's body mass index greater than or equal to the 70th percentile for age and sex\n* Teen lives with parent\u002Fcaregiver\n* Teen has access to a smart phone\n* Teen and caregiver speak and write in fluent English\n\nExclusion Criteria:\n\n* Teen has a medical condition that precludes them from participating in a group activity and\u002For any physical activity\n* Teen experiencing psychosis or suicidality\n* Teen lost a significant amount of weight in the 3 months prior to the study\n* Teen currently in another intensive health behavior and lifestyle treatment and\u002For sees a dietician more than once per month on average\n* Teen currently or planning to become pregnant\n* Teen unwilling to wear a continuous glucose monitor for assessments\n* Teen taking a medication known to impact weight and\u002For appetite","13 Years","18 Years",{"count":80,"type":22},50,[25],"Before the 1990s, obesity was rare among young people with type 1 diabetes (T1D), but now it is more common. Recent studies show that over 50% of young people with T1D will have overweight or obesity within five years of being diagnosed with T1D. Both obesity and T1D increase the risk of heart disease, and combined, these risks are even higher. Intensive health behavior and lifestyle treatments (IHBLTs) are proven to be effective for treating childhood obesity. However, managing T1D creates unique challenges that require adjustments to these treatments. For example, people with T1D need to eat even when they're not hungry to treat low blood sugar, blood sugar changes can make exercise harder, and some recommended \"free foods\" are high in unhealthy fats. Young people with T1D are also more likely to develop eating disorders. There is a need for IHBLTs that address these specific challenges and focus on preventing eating disorders in this group.\n\nTo address these needs, we developed the Type 1 Diabetes Adolescents for healthier Lifestyles (T1DAL) program, based on feedback from teenagers with T1D, their parents\u002Fcaregivers, and pediatric endocrinologists. The goal of this study is to test whether the T1DAL program can improve the health and wellbeing of teens compared to usual care.\n\nIn this study, about 50 teens will be randomly assigned to either the T1DAL program or to Usual Care. Those in the T1DAL group will take part in a 16-week program designed specifically for teens with T1D to improve eating habits and diabetes management. Those in the Usual Care group will continue with their regular endocrinology appointments. At the end of the study, the Usual Care group will be offered a shortened version of the T1DAL program. All participants will have their height, weight, blood glucose, eating habits, diabetes management behaviors, and mood measured at the start and end of the study. They will also answer questions to track unhealthy eating and weight control behaviors over time. Additional analyses will look at factors that may lead to these behaviors in real life.\n\nThis project builds on Dr. Warnick's previous work in pediatric obesity and T1D, and it supports the NIDDK's goal of reducing diabetes-related heart problems. T1DAL could become an important public health program to improve the health of teens with T1D.",[84,85,29],"Type 1 Diabetes","Eating Behavior",[87,88,84],"Teenagers","Diabetes","2026-05-12",{"date":91,"type":35},"2026-05-13",{"date":93,"type":35},"2025-08-01",{"date":95,"type":22},"2027-06-01",{"name":97,"class":42},"The Miriam Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":18,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":118,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":68},"100532095","early-life-intervention-in-pediatrics-supported-by-e-health-100532095","NCT06208345","Early Life Intervention in Pediatrics Supported by E-health","Early Life Intervention in Pediatrics Supported by E-health (ELIPSE I): Coaching Parents to Lower Obesity in Children. A Single-blind Randomized Controlled Parallel-group Clinical Trial.","ELIPSE-I","Inclusion Criteria:\n\n* German speaking parents\n* Any ethnic background\u002Frace\n* Children should live\u002Fgrow-up in the same household as the parental participant\n* Children with an age- and sex-matched BMI \\>97 centile according to Swiss national growth charts\n* Children who attend the outpatient weight management clinic at the Division of Pediatric Endocrinology at the University Children's Hospital Bern\n* Signed informed consent form from parent(s)\n\nExclusion Criteria:\n\n* Syndromic obesity\n* Known congenital disease affecting musculo-skeletal, cardiac or pulmonary function\n* Participation in another clinical trial targeting similar objectives","6 Years",{"count":108,"type":22},148,[25],"Childhood obesity in early life contributes to the development of specific NCDs, i.e. adult obesity. Unhealthy diet and low level of physical activity are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of NCDs. Early preventive measures to improve lifestyle behavior are of utmost importance. The aim of ELIPSE-I is to assess whether an eHealth application intervention for parents is feasible and efficacious in lowering total energy intake\u002Ftotal energy expenditure (TEI\u002FTEE) ratio in their children with BMI \\>97 centile (ELIPSE-I).",[112,113,29,114,115,116,117],"Adiposity","Childhood Obesity","Non-communicable Disease","Life Style","Behavior, Eating","Behavior, Health",[112,119,120,121,122],"Children","Adolescents","Prevention","eHealth","2026-02-12",{"date":125,"type":35},"2026-02-18",{"date":127,"type":35},"2024-02-16",{"date":129,"type":22},"2028-12-31",{"name":131,"class":42},"Insel Gruppe AG, University Hospital Bern",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":145,"conditions":146,"keywords":151,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":68},"100560330","phase-1-physiologic-response-to-bariatric-surgery-and-the-impact-of-adjunct-semaglutide-in-adolescents-100560330","NCT06575738","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents","Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide - in Adolescents (the PRESSURE Trial)","PRESSURE","Observation Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Male or female biological sex, age 12 through 24 years\n* In the preoperative pathway for vertical sleeve gastrectomy\n\nExclusion Criteria:\n\n* Planned Roux-en-Y gastric bypass\n* Hypothalamic obesity\n* Type 2 Diabetes\n* Current use of oral glucocorticoids (i.e. within 10 days of baseline visit)\n* Current use of insulin\n\nIntervention\u002FTreatment Phase\n\nInclusion Criteria:\n\n* Signed and dated informed consent form\n* Status post vertical sleeve gastrectomy\n* Male or female biological sex, age 12 through 24 years\n* Meeting minimum nutrition goals\n* Obesity: age 12-17 years: BMI ≥95th%ile for age\u002Fsex \\| age 18-24 years: BMI ≥ 30kg\u002Fm\\^2\n* If entering the Intervention phase from the Observational phase: ≤20% BMI loss at 1 year postop\n* If entering the Intervention phase from the existing patient pool: ≤20% BMI loss at 1-2 years postop\n\nExclusion Criteria:\n\n* Surgically correctable cause of suboptimal postoperative weight loss\n* Known hypersensitivity to any component of semaglutide\n* Personal or family history of medullary thyroid carcinoma\n* Personal history of multiple endocrine neoplasia type 2\n* Hypothalamic Obesity\n* Type 2 Diabetes\n* History of pancreatitis\n* Uncontrolled hypertension\n* Clinically significant arrhythmia or heart disease that could be exacerbated by increased heart rate\n* Malignant neoplasm within the last 5 years\n* Untreated thyroid disorder\n* Tanner Stage 1\n* Baseline alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥ 5x upper limit of normal\n* Baseline Creatinine \\>1.2mg\u002FdL\n* Active treatment for bulimia nervosa\n* Active major psychiatric disorder limiting informed consent\n* Suicidal ideation of type 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)\n* Intentional self-harm within the previous 1 month\n* Severe unmanaged depression, defined by Center for Epidemiological Studies Depression (CESD) score of 26 or greater and by clinical evaluation\n* Recent change to concomitant medications for hypertension, dyslipidemia, depression or anxiety (\\\u003C4 weeks prior to enrollment)\n* Use of oral glucocorticoids (within 10 days of baseline visit)\n* Use of metformin (within 3 months of baseline visit)\n* Use of insulin secretagogues (within 4 half-lives of the medication of baseline visit)\n* Current use of insulin\n* Use of anti-obesity medications (within 4 half-lives of the medication of baseline visit)\n* Current pregnancy\n* For females of reproductive potential: Plan to become pregnant in the next 8 months\n* For females of reproductive potential: Not on contraception (i.e. two forms of birth control for example oral birth control pills and condoms) for at least 1 month prior to enrollment and agreement to use these during study participation and for an additional 8 weeks after the final dose of study medication","24 Years",{"count":142,"type":22},40,[144],"PHASE1","The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.",[57,29,147,148,149,150],"Body-Weight Trajectory","Weight Loss Trajectory","Bariatric Surgery","Anti-obesity Agents",[57,152,149,153,154,155],"Anti-obesity medication","Bariatric Surgery Post Operative Outcomes","Semaglutide","Sleeve gastrectomy","2026-01-08",{"date":158,"type":35},"2026-01-12",{"date":160,"type":35},"2024-10-11",{"date":162,"type":22},"2027-10-01",{"name":164,"class":42},"University of Colorado, Denver",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":173,"maxAge":50,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100432937","a-multicenter-study-for-evaluating-a-digital-support-system-in-childhood-obesity-treatment-100432937","NCT04917601","A Multicenter Study for Evaluating a Digital Support System in Childhood Obesity Treatment","A Randomized Controlled Multicenter Study for Evaluating a Digital Support System in Childhood Obesity Treatment (EurEvira)","EurEvira","Inclusion Criteria:\n\n* Age \\>4.0 and \\\u003C17.0 years of age at inclusion\n* Obesity defined based on the International Obesity Task Force criteria iso-BMI 30 - 40 kg\u002Fm2\n* Willingness to participate in an obesity treatment clinical trial\n* Family ability to communicate in the language of the country of residence e.g. write and read messages in the mobile application\n* Parents having a smart phone and an email address\n\nExclusion Criteria:\n\n* Morbid obesity defined as iso-BMI\\>40kg\u002Fm2 independently of age\n* Endocrine disorders other than well controlled hypothyroidism\n* Metabolic disorders of importance for weight control - to be discussed\n* Treatment for depression and other psychiatric disorders during the last 6 months before inclusion\n* Pharmacological treatment of importance for weight control\n* Hypothalamic or monogenic obesity, e.g. syndromes and Mb Down\n* Severe neuropsychiatric disorders that could affect study compliance\n* Eating disorders requiring therapy during the last six months before inclusion or observed at the inclusion screening.","4 Years",{"count":175,"type":22},680,[25],"Evira is a digital support system newly developed for treatment of childhood obesity. Through daily weighings at home using a special scale together with a message function in the Evira application, enabling fast and easy communication with the clinic, parents and the clinicians can easily follow the child's weight development. The purpose of this randomized controlled study is to evaluate the effect of adding Evira to the already locally used life-style treatment of childhood obesity.",[113,29,179,180],"mHealth","Personalized Medicine",[182,183],"Obesity treatment","Digital support system","2025-09-30",{"date":186,"type":35},"2025-10-06",{"date":188,"type":35},"2022-05-24",{"date":190,"type":22},"2027-12",{"name":192,"class":42},"Karolinska Institutet",5,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":205,"conditions":206,"keywords":209,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":68},"100511160","phase-3-effect-of-amino-acids-on-hepatic-fat-content-in-adolescents-aminos-study-100511160","NCT05935826","Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)","AMINOS","Inclusion Criteria\n\n* Ages 13-18, Tanner stage 4-5\n* Suspected or diagnosed with NAFLD per fibroscan or liver biopsy within 6 months prior to enrollment as long as participants have not lost more than 5% of total body weight. Their MRI liver fat \\>5.5%\n* Diagnosis of non-alcoholic fatty liver disease (NAFLD) per hepatologist\n* Sedentary- less than 3 hours of moderate (jogging, swimming, etc.) exercise a week\n* BMI equal or greater than the 85th percentile for age and gender, this is overweight and obese categories\n\nExclusion Criteria\n\n* Use of medications known to affect insulin sensitivity: metformin, oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications.\n* Currently pregnant or breastfeeding women. Development of pregnancy during the study period will necessitate withdrawal from the study\n* Severe illness requiring hospitalization within 60 days\n* Diabetes, defined as Hemoglobin A1C \\> 6.4%\n* BMI percentile less than the 85th percentile for age and sex. Waist circumference \\>200 cm\n* Anemia, defined as Hemoglobin \\\u003C 11 mg\u002FdL\n* Diagnosed major psychiatric or developmental disorder limiting informed consent\n* Implanted metal devices that are not compatible with MRI\n* Use of blood pressure medications\n* Known liver disease other than NAFLD or AST or ALT \\>150 IU\u002FL",{"count":202,"type":22},55,[204],"PHASE3","Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo \"fake supplement\" for 2 months to see if the participants who get the protein supplement have less fat in the liver compared to participants who were in the placebo group. After the 2 month intervention, all participants can continue the study and will all receive the protein supplement for an additional 10-months.",[207,208,29],"Hepatic Steatosis","NAFLD",[210],"Amino Acid Supplement","2025-08-21",{"date":213,"type":35},"2025-08-28",{"date":215,"type":35},"2024-06-18",{"date":217,"type":22},"2026-08-31",{"name":164,"class":42},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":226,"sex":17,"minAge":227,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":231,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":248},"100439898","puberty-diabetes-and-the-kidneys-when-eustress-becomes-distress-panther-study-100439898","NCT05008276","Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)","PANTHER Study: Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress","Inclusion Criteria:\n\n* HbA1c ≥6.0% for untreated high-risk group\n* BMI ≥ 85th %ile for high-risk group\n* Normal HbA1c ≤5.6% for control group\n* Type 1 diabetes (T1D) Antibody negative\n\nExclusion Criteria:\n\n* History of Chronic kidney disease (CKD) or acute kidney injury (AKI)\n* Metabolic disorder prohibiting safe fasting\n* Iodine or penicillin allergy\n* Pregnancy\n* Thrombophilia\n* MRI contraindications\n* Hormone therapy",true,"8 Years","14 Years",{"count":230,"type":22},100,"OBSERVATIONAL","Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.",[234,235,29,236,237,238],"Type 2 Diabetes Mellitus","Diabetic Kidney Disease","Pre Diabetes","Kidney Hypoxia","Puberty","2025-03-20",{"date":241,"type":35},"2025-03-24",{"date":243,"type":35},"2021-09-27",{"date":245,"type":22},"2027-12-01",{"name":247,"class":42},"Petter Bjornstad",2,{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":68},"100563460","the-effect-of-time-restricted-feeding-on-body-composition-and-some-metabolic-parameters-in-obese-adolescents-100563460","NCT06616454","The Effect of Time-Restricted Feeding on Body Composition and Some Metabolic Parameters in Obese Adolescents","Inclusion Criteria:\n\n* Adolescents aged 12-18 with puberty stage:5\n* Obese adolescents with a metabolic disorder (such as fatty liver, insulin resistance, prediabetes, dyslipidemia) (BMI≥95th percentile for age)\n* Those who have a stable body weight for 3 months before the start of the study (current weight gain or loss \\\u003C4 kg)\n* Those who own and can use a Smartphone with Apple iOS or Android operating system\n* Those who speak, read and understand Turkish\n\nExclusion Criteria:\n\n* Those with any endocrine disorder, metabolic, chronic or major psychiatric disease other than obesity, insulin resistance, dyslipidemia, prediabetes, fatty liver\n* Polycystic ovary syndrome (PCOS)\n* Those with physical or mental disabilities\n* Those with allergies, intolerances or eating disorders\n* Those who smoke and drink alcohol\n* Use of drugs that may affect study results, circadian rhythms or metabolism (such as antidiabetics, steroids, beta blockers, adrenergic stimulating agents, laxatives, etc.)",{"count":256,"type":22},60,[25],"Obesity is now recognized as a serious public health problem. It is known that obesity seen in adolescence is largely carried over to adulthood. Therefore, its treatment is important both in terms of protecting current health and preventing diseases in adulthood. Reducing energy intake plays an important role in the treatment of obesity. However, long-term adherence and effectiveness to energy restriction appear to be limited. Therefore, the need for interventions that are \"effective in body weight loss\" and \"accessible, simple and lifestyle modification to increase dietary compliance\" is clear. Time-restricted feeding is a specialized intermittent fasting protocol that includes consistent fasting and eating periods over a 24-hour cycle by supporting circadian rhythms. Especially in the adult population, positive effects of time-restricted feeding such as weight loss and blood glucose regulation are observed. However, there are limited data on this subject for adolescents. Today, the Mediterranean diet, which is one of the nutrition models that supports health, is a beneficial nutritional model that reduces body weight and obesity-related comorbidities by limiting total energy intake. However, no study has been found in the literature in which the effectiveness of time-restricted nutrition, which is a new and promising approach, and the Mediterranean diet, which is a sustainable diet model, are evaluated together. Therefore, in this study, it was aimed to evaluate the effects of planned time-restricted nutrition compatible with circadian rhythm and energy-restricted feeding planned according to the Mediterranean diet model on body composition and various metabolic parameters in obese adolescents. 60 obese adolescents aged 12-18 years will be included in this randomized controlled and parallel design study. Participants will be randomized to one of two treatment groups for a 12-week intervention. The time-restricted feeding group will form the intervention group of the study, and the energy-restricted feeding group will form the control group. Anthropometric measurements of the participants at the beginning and end of the study will be taken, and various biochemical parameters will be evaluated with the body composition and blood samples to be taken. As a result of the study, it is expected to determine the effectiveness of time-restricted feeding compared to energy-restricted feeding in terms of dietary compliance, body composition and biochemical changes.",[29],[30,261,262,263],"Body Composition","Healthy Diet","Time-Restricted Eating","2025-02-24",{"date":266,"type":35},"2025-02-25",{"date":268,"type":35},"2024-10-14",{"date":270,"type":22},"2025-08-15",{"name":272,"class":42},"Sümeyra Başar",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":226,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":288,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":68},"100487125","dietary-modulation-of-gut-microbiota-in-overweightobese-adolescents-and-covid-19-infection-100487125","NCT05623007","Dietary Modulation of Gut Microbiota in Overweight\u002FObese Adolescents and COVID-19 Infection","Dietary Modulation of Gut Microbiota on Nutritional Status and COVID-19 Infection in Adolescents: Gut-Lung-Axis","DIVINE","Inclusion Criteria:\n\n1. living in Jakarta, Surabaya, and Yogyakarta City for at least 6 months permanently;\n2. apparently healthy;\n3. male and female, age 12-17 years old;\n4. overweight or obese (BMI-for-age z-score \\>+1SD);\n5. have completed at least two dosages of COVID-19 vaccine, the vaccine must be CoronaVac® (Sinovac);\n6. minimal 6 months post vaccinated prior to recruitments.\n7. parents willing to sign the informed consent and adolescents give informed assent;\n8. Must have an active health insurance, for instance BPJS or similar health insurance.\n\nExclusion Criteria:\n\n1. having a history of COVID-19 infection within the last month confirmed by PCR or antigen from health care facilities or independent laboratory;\n2. having a history of chronic and non-communicable diseases, congenital diseases, and disabilities;\n3. reported current diagnosed as suspected active Tuberculosis (primary lung TB, miliary TB, bleeding cough bone TB, meningitis TB);\n4. having a history of gastrointestinal or malabsorption disorder (such as celiac disease and inflammatory bowel disease) within the last three months or during the study;\n5. taking antibiotics during 2 weeks before the start of the study (adolescents will be included after 3 weeks of last antibiotic intake);\n6. taking other medications or having diseases that may influence the immune response - i.e. immune deficiencies, immunosuppressants medications, blood transfusion or other blood products;\n7. taking insulin and\u002For anti-dyslipidemia medication;\n8. being pregnant and\u002For breastfeeding.",{"count":282,"type":22},440,[25],"Probiotic intervention has been currently suggested to provide supportive benefits in promoting health, including alleviating disease symptoms, protecting against diarrhea and respiratory infection, affecting growth and modulating the immune system by improving the beneficial gut microbiota colonization, giving direction on the gut-lung-axis pathway. This indicates that probiotics may become alternative to improve nutrition and reduce the risk of viral infections which may reduce the risk against Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). Introduction to probiotics during adolescence can alleviate inflammation and invert dysbiosis. However, evidence on the effect of probiotic supplementation on enhancing antibody response to SARS COV-2 in adolescents is lacking. Moreover, previous studies showed the potential effect of probiotic supplementation to improve overweight and obesity in adolescents. A bi-directional relationship exists among nutrition, infection, and immunity as changes in one element will affect the others. The main objective of this study is to investigate the effect of dietary modulation of overweight and obese adolescent's gut microbiota through probiotic supplementation combined with healthy eating and physical activity counseling and psychosocial stimulation on nutritional status and antibody response to COVID-19 vaccination. This trial will conduct a 20-week intervention for overweight and obese adolescents.",[286,287,29],"Health Behavior","Child Development",[289,290,291,292,293],"adolescent","probiotics","COVID-19","overweight","obese","2025-02-23",{"date":266,"type":35},{"date":297,"type":35},"2022-11-01",{"date":299,"type":22},"2025-12-30",{"name":301,"class":42},"Indonesia University",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":319,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100556108","treatment-and-handling-severe-obesity-related-comorbidities-in-adolescents-through-exercise-100556108","NCT06520800","Treatment and Handling Severe Obesity-Related Comorbidities in Adolescents Through Exercise","THOR-X","Inclusion Criteria:\n\n* adolescents aged 13 to 18 years;\n* of any gender (including transgender adolescents);\n* with severe obesity (≥3.0 BMI z-score) \\[24\\];\n* with any obesity-related comorbidity (e.g., hypertension, IR or DMT2, dyslipidemia, eating disorders, depression\u002Fanxiety);\n* at least 6 months of follow-up at the Pediatric Obesity Clinic (HSM, CHULN) at the time of recruitment;\n* living in Lisbon area;\n* informed consent\u002Fassent signature.\n\nExclusion Criteria:\n\n* major or unstable clinical conditions (other than obesity or its related comorbidities);\n* inability to perform regular PA;\n* pregnancy;\n* mental disorders;\n* smoking habits;\n* being involved in another weight loss program.",{"count":310,"type":22},24,[25],"The main objective of this project is to analyze the effect of a tailor-made, one-to-one, exercise program (aiming to treat and handle obesity-related comorbidities in adolescents with severe obesity at high risk of cardiovascular disease development) on BMI z-score, specific comorbidities, and other health-related indicators.\n\nThis project will further allow to analyze the long-term impact of the exercise program not only on clinical parameters, but also on the interaction with drug-treatment, health-related behaviors, and quality of life, further contributing to the understanding of the individual characteristics associated with a positive exercise response and frequency.\n\nThe secondary objective of the THOR-X project is to build an educational toolkit, based on project results and relevant literature, addressed to health and exercise professionals, in order to improve management of adolescents with obesity, in particular those with severe obesity.",[29,314,315,316,317,318],"Hypertension,Essential","Non-Alcoholic Fatty Liver Disease","Dyslipidemias","Metabolic Disease","Metabolic Syndrome",[29,182,320,321],"Physical activity","Exercise","2024-07-25",{"date":324,"type":35},"2024-07-29",{"date":326,"type":22},"2025-01",{"date":328,"type":22},"2028-12",{"name":330,"class":42},"University of Lisbon",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":339,"targetDuration":4,"studyType":231,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100301368","registry-on-obesity-surgery-in-adolescents-100301368","NCT03203161","Registry on Obesity Surgery in Adolescents","A Prospective Observational Cohort Study Collecting Coordinated Clinical, Epidemiological, and Behavioural Data to Assess Safety and Efficacy of Surgical Treatment in Adolescent Morbid Obese Patients","ROSA","Inclusion Criteria:\n\n* BMI (or projected BMI) \\> 40 kg\u002Fm² (projected BMI = weight over the age- and gender-specific BMI z-score defined as severe obesity corresponding at a projected BMI of 40 at the age of 18y) OR\n* BMI ((or projected BMI) \\> 35 kg\u002Fm² (projected BMI = weight over the age- and gender-specific BMI z-score defined as severe obesity corresponding at a projected BMI of 35 at the age of 18y) + 1 or more of the following obesity-related comorbid conditions: Obstructive Sleep Apnea Syndrome, Non-alcoholic steatohepatitis, type 2 diabetes, hypertension, benign intracranial hypertension.\n* Minimum 6 months of organized weight loss attempts before surgery (multidisciplinary follow-up)\n* Completed most of their linear growth (Tanner stage ≥ IV, bone age ≥ 13 years in girls and ≥ 14 years in boys assessed by the Tanner and Whitehouse method)\n* Capability and willingness to adhere to postoperative guidelines and prolonged surveillance\n* Informed Consent Form (ICF) signed by patient and parents (or legal guardian)\n\nExclusion Criteria:\n\n* psychological\u002Fpsychiatric disorders that are decompensated or not efficiently treated\n* severe and unstable eating disorders (e.g. binge-eating)\n* signs of addictions or addictive behavior (alcohol or substance abuse)\n* pregnancy or breastfeeding\n* life-threatening multisystem organ failure\n* uncontrolled or metastatic malignancy\n* uncontrolled HIV infection\n* hypercarbic respiratory failure\n* active systemic infection or untreated endocrine dysfunction\n* diseases threatening in the short term or lack of care (self-care or access to family or social support)\n* medically correctable causes of obesity",{"count":80,"type":22},"While bariatric surgery is established as a safe and effective alternative with well-defined risks for severely obese adults, little has been published on its use in children.\n\nThere are many unresolved questions concerning the long-term metabolic and psychological consequences of bariatric surgery in adolescents, and the difference with the adult population. The appropriate timing for bariatric surgery in young people, and the predictors of success and safety still need to be determined.\n\nThe aim of this long-term prospective study is therefore to establish the safety and efficacy profile of surgical procedures and to clarify whether reductions in morbidity and mortality outweigh the risks of serious surgical complications and lifelong nutritional deficiencies.",[342,149,29],"Morbid Obesity","2019-02-11",{"date":345,"type":35},"2019-02-12",{"date":347,"type":22},"2019-09",{"date":349,"type":22},"2029-09",{"name":351,"class":42},"Queen Fabiola Children's University Hospital",3]